Dudediligence.

Amgen Inc

AMGNNASDAQ · Biological Products, (No Diagnostic Substances)
Write an idea

Insiders

Last 12 months

Sales planned on beside the trades reported on , and whether each names a .

Planned ·

$29.3M

10 notices · 78,049 sh

Oct 2025 to Oct 2026

Reported ·

$25.2M

8 sales · 0 buys

Oct 2025 to Jun 2026

The two figures cover different periods.

None of the 8 reported sales carry the 10b5-1 box. Together they are 0.01% of the shares on issue.

PLANNED · FORM 144Oct 2025 to Oct 2026REPORTED · FORM 4Oct 2025 to Jun 2026N2025DJ2026FMAMJJASO2026-08-13: Khosla Rachna, Form 1442026-08-11: Khosla Rachna, Form 1442026-08-06: Grygiel Nancy A., Form 1442026-08-06: Derek Miller, Form 1442026-05-04: Grygiel Nancy A., Form 1442026-02-26: Santos Esteban, Form 1442026-02-19: Busch Matthew C., Form 1442025-11-20: Grygiel Nancy A., Form 1442025-11-12: Khosla Rachna, Form 1442025-11-12: Gordon Murdo, Form 1442025-11-12: Gordon Murdo, sold2025-11-12: Khosla Rachna, sold2025-11-20: Grygiel Nancy A., sold2026-02-19: Busch Matthew C., sold2026-02-26: Santos Esteban, sold2026-05-04: Grygiel Nancy A., sold
under a no plan named▼ salesize is dollars

Form 144 notices, newest first

2026-08-13Khosla Rachna, SVP, Business Development$516,775
1,252 shno plan dateForm 4s on file end Jun 23144 ↗
2026-08-11Khosla Rachna, SVP, Business Development$828,420
2,000 shno plan dateForm 4s on file end Jun 23144 ↗
2026-08-06Grygiel Nancy A., SVP & CCO$1,193,940
2,970 shno plan dateForm 4s on file end Jun 23144 ↗
2026-08-06Derek Miller, SVP, Human Resources$1,574,867
3,890 shno plan dateForm 4s on file end Jun 23144 ↗
2026-05-04Grygiel Nancy A., SVP & CCO$400,450
1,237 shno plan date144 ↗
Form 4, 2026-05-05: sold 1,237 at $323.73The price reported is an average price of $323.7272 per share. Full information regarding the number of shares purchased at each separate price within the range is available upon request by the SEC staff, the issuer or a security holder of... Form 4 ↗
2026-02-26Santos Esteban, EVP, Operations$20.8M
54,792 shno plan date144 ↗
Form 4, 2026-03-02: sold 54,792 at $379.12Includes shares sold to cover the option exercise price and required withholding taxes in connection with the exercise of expiring options. Form 4 ↗
2026-02-19Busch Matthew C., VP, Finance & CAO$375,000
1,000 shno plan date144 ↗
Form 4, 2026-02-20: sold 1,000 at $375.79These shares include 60 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's... Form 4 ↗
2025-11-20Grygiel Nancy A., SVP & CCO$1,058,667
3,139 shno plan date144 ↗
Form 4, 2025-11-21: sold 3,139 at $337.26The price reported is an average price. The prices ranged from $337.17 to $337.69 per share. Full information regarding the number of shares purchased at each separate price within the range is available upon request by the SEC staff, the... Form 4 ↗
2025-11-12Khosla Rachna, SVP, Business Development$300,304
890 shno plan date144 ↗
Form 4, 2025-11-13: sold 890 at $336.24The price reported is an average price. The prices ranged from $336.2219 to $336.30 per share. Full information regarding the number of shares purchased at each separate price within the range is available upon request by the SEC staff... Form 4 ↗
2025-11-12Gordon Murdo, EVP, Global Commercial Ops$2,319,805
6,879 shno plan date144 ↗
Form 4, 2025-11-13: sold 6,879 at $336.83The price reported is an average price. The prices ranged from $336.7301 to $337.0500 per share. Full information regarding the number of shares purchased at each separate price within the range is available upon request by the SEC staff... Form 4 ↗